What are Vertex's primary revenue sources and how are they trending?

Vertex's primary revenue sources are royalties from marketed drugs and collaborative research and development (R&D) revenue. In 2004, total revenues increased significantly to $102.7 million, up from $69.1 million in 2003. Royalties grew to $17.3 million, and collaborative R&D revenue surged to $85.4 million, largely due to new collaboration agreements and milestone payments.

What is Vertex's financial performance and outlook for profitability?

Vertex continued to operate at a net loss in 2004, reporting a loss of $166.2 million. While this is an improvement from the $196.8 million loss in 2003, the company expects to incur significant operating losses in 2005 due to ongoing substantial investments in R&D. Vertex has not predicted when it will become profitable.

What are the key developments in Vertex's drug pipeline for 2004?

Vertex advanced several key drug candidates in 2004. In the viral diseases area, merimepodib and VX-950 continued development for Hepatitis C, while VX-385 progressed in Phase II for HIV. For inflammatory and autoimmune diseases, VX-765 entered Phase II development for psoriasis, and VX-702 continued Phase II studies for inflammatory diseases. In oncology, VX-680 entered Phase I development with Merck.

How is Vertex managing its substantial R&D investments and what is its strategy for funding future development?

Vertex manages its R&D investments through a strategy that balances internally controlled programs with those conducted by collaborators. The company relies heavily on funding from strategic collaborations, milestone payments, and royalties. The substantial cash reserves of $392.3 million at the end of 2004 provide a significant financial buffer, but Vertex anticipates needing additional capital in the future, potentially through further collaborations or capital market transactions, to sustain its R&D efforts.

VRTX 10-K FY2004 Annual Report — Revenue, Net Income, EPS

Summary

Vertex Pharmaceuticals Inc. reported its 2004 annual results, highlighting a significant increase in total revenues to $102.7 million, driven by growth in both royalty income and collaborative research and development revenue. Despite this revenue growth, the company continued to incur net losses, with a reported net loss of $166.2 million for the year. This loss is attributed to substantial ongoing investments in research and development, which totaled $192.2 million, aimed at advancing a diverse pipeline of drug candidates targeting serious diseases such as HIV, Hepatitis C, inflammatory and autoimmune disorders, and cancer. Key to the company's strategy are its collaborations with major pharmaceutical partners like GlaxoSmithKline, Novartis, and Merck, which provide crucial funding and development resources. Vertex has two marketed HIV drugs, Lexiva/Telzir and Agenerase, generating royalty income, and is actively developing promising candidates like merimepodib and VX-950 for Hepatitis C. The company's financial position remains robust with $392.3 million in cash, cash equivalents, and marketable securities at year-end 2004, providing a runway for continued investment in its drug development efforts.

Key Highlights

1Total revenues increased by 48.6% to $102.7 million in 2004, compared to $69.1 million in 2003, primarily driven by higher royalty income and collaborative R&D revenue.

2The company reported a net loss of $166.2 million for 2004, a decrease from the $196.8 million net loss in 2003, indicating progress in managing expenses relative to revenue growth.

3Research and development expenses decreased slightly to $192.2 million in 2004 from $199.6 million in 2003, reflecting a strategic focus on development activities for key viral and inflammatory disease programs.

4Vertex has a diverse pipeline with key drug candidates in Phase II development for chronic Hepatitis C (merimepodib, VX-385) and inflammatory/autoimmune diseases (VX-765, VX-702), alongside early-stage oncology and pain candidates.

5The company secured significant new collaborations in 2004 with CFFT, Mitsubishi Pharma, and Merck, along with an amendment to its Novartis agreement, bolstering its funding and development capabilities.

6Vertex ended 2004 with a strong cash position of $392.3 million, providing financial flexibility to fund ongoing operations and R&D investments.

7The company is managing significant off-balance sheet obligations related to its Kendall Square lease, with an estimated net ongoing liability of $55.8 million at year-end 2004.

Frequently Asked Questions